Medtronic has reportedly filed for pre-market approval from the FDA for its MiniMed 670G “artificial pancreas,” which is designed to automatically track and adjust blood sugar levels in patients with diabetes, and expects the federal safety watchdog to issue a decision within a year.
The device measures blood glucose every 5 minutes to keep patients within their target range, according to Bloomberg. Medtronic’s PMA bid is backed by a 124-patient trial that showed better blood glucose control than with manual testing and insulin administration.
